{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T20:53:08Z","timestamp":1779223988684,"version":"3.51.4"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005888","name":"Uniwersytet Medyczny w Lodzi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>The aim of this EMINENTS prospective, single-center, open-label, single-arm study was to evaluate the cumulative efficacy and safety of reduced doses of everolimus (maintenance therapy) in patients with tuberous sclerosis and subependymal giant cell astrocytoma (SEGA).<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> The trial included 15 patients who had undergone at least 12 months of treatment with a standard everolimus dose. The dose of everolimus was reduced to three times a week, with a daily dose as in standard regimen. Data of 14 patients were analyzed. SEGA volume (SV) was evaluated at study entry and subsequent time points by an experienced radiologist. Adverse events (AEs) noted during maintenance therapy were compared to the AEs of standard dose period.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Patients were followed over a mean duration 58.37 months (95%CI: 45.95\u201370.78). The differences in SEGA volume between subsequent time points (0, 3, 6,12, 18, 24, 36, 48, and 60 months) were not statistically significant (<jats:italic>p<\/jats:italic> = 0.16). At the end of the study, 7 out of 10 patients had stable SEGA volume. No clinical symptoms of progression were observed in any patients. No patient or tumor-related risk factors of progression were identified. Regarding AEs, infections (stomatitis, bronchitis, diarrhea) and laboratory abnormalities (neutropenia, anemia, hyperglycemia) occurred less frequently during maintenance therapy compared to the standard dose regimen.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Final results from EMINENTS study confirm that maintenance therapy with everolimus might represent a rational therapeutic option for patients TSC and SEGA after effective full dose treatment. It could be an option for patients who experienced everolimus-related AEs, instead of discontinuation of therapy. Careful evaluation of possible progression, especially concerning first six months of maintenance therapy should be advised.<\/jats:p><jats:p><jats:bold>Clinical Trial Registration:<\/jats:bold><jats:ext-link>www.drks.de<\/jats:ext-link>, identifier DRKS00005584.<\/jats:p>","DOI":"10.3389\/fneur.2021.581102","type":"journal-article","created":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T06:51:21Z","timestamp":1617951081000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Maintenance Therapy With Everolimus for Subependymal Giant Cell Astrocytoma in Patients With Tuberous Sclerosis \u2013 Final Results From the EMINENTS Study"],"prefix":"10.3389","volume":"12","author":[{"given":"Katarzyna","family":"Bobeff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolina","family":"Krajewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dobromila","family":"Baranska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Kotulska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergiusz","family":"Jozwiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Mlynarski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Trelinska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3389\/fneur.2019.00821","article-title":"Clinical characteristics of subependymal giant cell astrocytoma in tuberous sclerosis complex","volume":"10","author":"Jansen","year":"2019","journal-title":"Front Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1177\/0883073813501870","article-title":"Subependymal giant cell astrocytomas in patients with tuberous sclerosis complex:: considerations for surgical or pharmacotherapeutic intervention","volume":"29","author":"Wheless","year":"2014","journal-title":"J Child Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/ana.24523","article-title":"Everolimus for subependymal giant cell astrocytoma: 5-year final analysis","volume":"78","author":"Franz","year":"2015","journal-title":"Ann Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0158476","article-title":"Long-term use of everolimus in patients with tuberous sclerosis complex: final results from the EXIST-1 study","volume":"11","author":"Franz","year":"2016","journal-title":"PLoS ONE."},{"key":"B7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00467-014-2949-6","article-title":"The effects of everolimus on tuberous sclerosis-associated lesions can be dramatic but may be impermanent","volume":"30","author":"Miller","year":"2015","journal-title":"Pediatr Nephrol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/CAD.0000000000000207","article-title":"Complications of mammalian target of rapamycin inhibitor anticancer treatment among patients with tuberous sclerosis complex are common and occasionally life-threatening","volume":"26","author":"Trelinska","year":"2015","journal-title":"Anticancer Drugs."},{"key":"B9","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/pbc.25368","article-title":"Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis","volume":"62","author":"Trelinska","year":"2015","journal-title":"Pediatr Blood Cancer."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pbc.26347","article-title":"Maintenance therapy with everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis (the EMINENTS study)","volume":"64","author":"Trelinska","year":"2017","journal-title":"Pediatr Blood Cancer."},{"key":"B11","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10334-017-0614-3","article-title":"What are the true volumes of SEGA tumors? Reliability of planimetric and popular semi-automated image segmentation methods","volume":"30","author":"Stawiski","year":"2017","journal-title":"Magn Reson Mater Physics, Biol Med."},{"key":"B12","first-page":"0","volume-title":"Common Terminology Criteria for Adverse Events v4.0","year":"2009"},{"key":"B13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jchromb.2013.03.014","article-title":"Two rapid ultra performance liquid chromatography\/tandem mass spectrometry (UPLC\/MS\/MS) methods with common sample pretreatment for therapeutic drug monitoring of immunosuppressants compared to immunoassay","volume":"928","author":"Tszyrsznic","year":"2013","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12883-016-0658-4","article-title":"EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex","volume":"16","author":"Fogarasi","year":"2016","journal-title":"BMC Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1002\/pbc.25573","article-title":"Dose-level response rates of mtor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA)","volume":"62","author":"Weidman","year":"2015","journal-title":"Pediatr Blood Cancer."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-017-0581-9","article-title":"Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide","volume":"12","author":"Davies","year":"2017","journal-title":"Orphanet J Rare Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.pharep.2016.01.005","article-title":"Management of side effects of mTOR inhibitors in tuberous sclerosis patients","volume":"68","author":"Sadowski","year":"2016","journal-title":"Pharmacol Reports."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-019-1012-x","article-title":"Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis","volume":"14","author":"Li","year":"2019","journal-title":"Orphanet J Rare Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s11910-016-0708-8","article-title":"mTOR inhibitors in children: current indications and future directions in neurology","volume":"16","author":"Jeong","year":"2016","journal-title":"Curr Neurol Neurosci Rep."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.581102\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T06:51:26Z","timestamp":1617951086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.581102\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,9]]},"references-count":19,"alternative-id":["10.3389\/fneur.2021.581102"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.581102","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,9]]},"article-number":"581102"}}